FDA panel votes 3-14 that Abbott (ABT) has not found right Humira dose
- Wall Street dips on Trump protectionism, Qualcomm drag
- Barclays Downgrades Apple (AAPL) to Equalweight, Concerned India/China Will not Emerge As Growth Catalysts
- DuPont (DD) Tops Q4 EPS by 9c; Sees Merger Closing in First Half
- Yahoo! (YHOO) Tops Q4 EPS by 4c; Sees Verizon Deal Closing in Q2, Not Q1
- SAP (SAP) Q4 IFRS Revenues Rises 7%, Boosts 2020 Outlook
FDA panel votes 3-14 that Abbott (NYSE: ABT) has not found right Humira dose.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Absolute to Host Conference Call for Fiscal 2017 Second Quarter Financial Results
- ADMA Biologics (ADMA) to Acquire Assets from Biotest Pharmaceuticals
- New Study Demonstrates Spinal Cord Stimulation Can Reduce or Stabilize Opioid Use Among Chronic Pain Patients
Create E-mail Alert Related CategoriesFDA, General News
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!